Amgen's Strategic Shift: Pivoting the Pipeline for Future Growth

Amgen targets $37-38.4B in 2026 sales, pivoting to next-gen drugs like monthly-dose obesity candidate MariTide to offset biosimilar competition.

The biotechnology leader Amgen is navigating a significant strategic transformation. With established revenue drivers facing increased competition, the company is aggressively reshaping its development portfolio to secure its long-term market position. A key component of this shift is its focus on next-generation therapeutics, including a potential disruptor in the lucrative weight-loss drug sector.

Financial Targets Amid Portfolio Transition

Following a record annual revenue of $36.8 billion, Amgen has set its sights on a 2026 sales target ranging between $37.0 and $38.4 billion. This growth is expected to be driven by a more diversified product base. Management anticipates that legacy brands, including Prolia and XGEVA, will cede substantial ground due to the encroachment of biosimilar competitors.

To counter these anticipated declines, the firm is pushing for volume expansion within its cardiovascular and oncology segments. The operating margin, projected to be approximately 43% at the start of the year, is viewed as a critical indicator of financial discipline throughout this period of change. The effectiveness of this strategy will be closely monitored as the company integrates its rare disease division and seeks new patient initiations in immunology to offset older product losses.

MariTide: A Potential Standout in Metabolic Medicine

Central to Amgen's long-term growth narrative is its investigational drug, MariTide. This bispecific antibody-peptide conjugate is currently in multiple Phase 3 trials for treating obesity and type 2 diabetes. Its most significant competitive advantage may stem from its dosing schedule.

While current leading GLP-1 therapies typically require weekly administration, Amgen is exploring monthly or even quarterly dosing intervals for MariTide. In an increasingly crowded market for metabolic diseases, this enhanced patient convenience could serve as a powerful differentiator, potentially redefining treatment standards.

• April 30, 2026: First-quarter financial results publication.
• May 19, 2026: Annual shareholder meeting.

The quarterly figures due on April 30 will provide early evidence of how well the company's strategic initiatives are mitigating revenue pressure. Investors will also scrutinize whether the clinical development of MariTide remains on track, as its success is pivotal for securing a durable position in metabolic medicine.